Results 221 to 230 of about 32,623 (326)

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

JEADV Clinical Practice, Volume 5, Issue 2, Page 402-414, June 2026.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek, Iris Zalaudek, Karolina Zarańska, Bożena Cybulska‐Stopa   +3 more
wiley   +1 more source

Subacute cutaneous lupus erythematosus secondary to intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy: A case report. [PDF]

JAAD Case Rep
Smith K, Nathoo R, Foss MG.
europepmc   +1 more source

Anifrolumab Treatment in Cutaneous Lupus Erythematosus with and without systemic involvement: A Retrospective Study [PDF]

Xavier Bosch‐Amate, Lluís Corbella‐Bagot, M. Ayguasanosa, Priscila Giavedoni, Olga Araújo, Gerard Espinosa, Ricard Cervera, José A. Gómez‐Puerta, Juan Ignacio Aróstegui, Anna Mensa‐Vilaró, José M. Mascaró   +10 more
openalex   +1 more source

Ashes to Rashes: An Exploration of the Intersection Between Smoking and Cutaneous Lupus Erythematosus. [PDF]

Biomolecules
Homer RO, Eldaboush A, Kang D, Ahmed NS, Khosravi-Hafshejani T, Liu ML, Werth VP.   +6 more
europepmc   +1 more source

Susceptibility of T cell receptor-αchain knock-out mice to ultraviolet B light and fluorouracil: a novel model for drug-induced cutaneous lupus erythematosus [PDF]

, 2004
Takashi Yoshimasu, Takeshi Nishide, Naohiro Seo, Akihisa Hiroi, T. Ohtani, Koji Uede, Fukumi Furukawa   +6 more
openalex   +1 more source

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

Movement Disorders, Volume 41, Issue 6, Page 1492-1501, June 2026.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar, Pinky Agarwal, Karen Anderson, Daniel Claassen, Marissa Dean, Andrew Duker, Burton Scott, Benjamin Hoehn, Ann Mongan, Ping Lin, Ellen Cahir‐McFarland, Lori Taylor, Glenn Morrison, Ted Yednock, Sanjay Keswani, Henk‐Andre Kroon   +15 more
wiley   +1 more source

Update on cutaneous lupus erythematosus

Indian Journal of Dermatology, Venereology, and Leprology, 2012
openaire   +2 more sources

Cell membrane‐coated nanoparticles for dermatological diseases

VIEW, Volume 7, Issue 3, June 2026.
Skin disorders are challenging to treat due to complex barrier functions and limited conventional therapies. Biomimetic cell membrane‐coated nanoparticles (CM‐NPs) offer a superior nanomedicine approach by evading immune detection and enabling precise targeting.
Shuaijun Zou, Baojie Zhang, Yuanjie Zhu
wiley   +1 more source

Focus on Interferon Signature in Cutaneous Lupus Erythematosus: Novel Therapies From Better Understanding of the Pathogenesis. [PDF]

J Immunol Res
Gao M, Zhang N, Xia Y.
europepmc   +1 more source

Progressive disseminated histoplasmosis mimicking acute cutaneous lupus erythematosus in an immunocompetent woman

Lipsa Kumari, Vaishnavi Verma, Sonali Dixit, Neha Taneja   +3 more
openalex   +1 more source